SkinBioTherapeutics PLC (AIM: SBTX) has reported encouraging early trading momentum for its current financial year, with management guidance pointing towards 2026 results aligned with market expectations. The AIM-listed group forecasts revenues of £6.2 million alongside adjusted EBITDA of £0.7 million, representing continued progression in its financial trajectory.
The anticipated performance reflects accelerating contribution from recent product launches and the growing integration of businesses acquired over the preceding 24 months. The company specialises in skin health through cosmetic ingredients, supplements and topical formulations, positioning itself across multiple distribution channels within the sector.
The outlook for the current period builds upon operational developments achieved during 2025. Management highlighted the expanded retail presence of its AxisBiotix product range through Superdrug stores, combined with the initial market introduction of cosmetic formulations incorporating Zenakine. This ingredient represents the Croda-branded commercialisation of the company’s proprietary SkinBiotix technology platform.
Financial results for the 12 months ending June 2025 demonstrated substantial year-on-year growth, with revenue advancing 284 per cent to £4.6 million. This performance was driven by direct AxisBiotix sales, early royalty streams from the Zenakine licensing arrangement, a full year of trading from Dermatonics and nine months of contribution from Bio-Tech Solutions following its acquisition in late 2024.
The adjusted EBITDA loss narrowed materially to £0.4 million during the period, whilst the operating loss improved 61 per cent to £1.1 million. Balance sheet strength was reinforced through year-end cash holdings of £4.8 million, bolstered by cash generation from acquired operations and capital raises totalling £5.8 million executed during August 2024 and June 2025.
Operational highlights from the financial year included the global launch of Zenakine through Croda in April, marking the commercial realisation of the SkinBiotix ingredient licensing strategy. The AxisBiotix brand secured a two-year exclusive supply agreement with Superdrug, resulting in distribution across more than 180 retail locations for both product lines.
The Dermatonics acquisition delivered revenues of £2.2 million with EBITDA contribution of £0.5 million, whilst Bio-Tech Solutions generated £1.4 million of turnover during its partial year of ownership. Post-period developments have focused on integrating manufacturing and packaging capabilities across the enlarged group to support broader product development initiatives.
Chief executive Stuart Ashman characterised the period as one where the cumulative benefits of partnership arrangements and corporate acquisitions are becoming increasingly visible within financial performance. He indicated expectations for sustained growth across both direct consumer sales and indirect licensing revenues throughout the current financial year.
The company’s strategic positioning combines proprietary ingredient technology commercialised through business-to-business licensing with direct-to-consumer branded product sales across expanding retail networks. This dual revenue model provides diversified income streams across different segments of the personal care and cosmetics market.
